genital-urinary symptoms of
menopause (GSM)
ABOUT THE PROBLEM
TREATMENT OPTION FOR POSTMENOPAUSAL VAGINAL ATROPY
Vulvovaginal atrophy (VVA) affects up to 50%–60% of postmenopausal women who often don't seek treatment. Although more than half of menopausal women experience symptoms such as dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia, and spotting during intercourse, research indicates only 25% of patients with symptoms of VVA will receive adequate therapy. Women may be embarrassed to discuss these issues with their healthcare provider or feel it is a part of the aging for which nothing can be done. *
What if we could do something pre-emptively that would prevent or minimize many of the symptoms that accompany menopause and the development of VVA? What if we provided women with a product they could use before these issues developed?
That’s what we are excited about at New Attitude. Follow us and see why we have a New Attitude.
*Naumova and Castelo-Branco, Current treatment options for postmenopausal vaginal atrophy, International Journal of Women’s Health 2018:10 387–395
the market
THE OPPORTUNITY
In Canada, there are more than 10 million women over the age of 40 in perimenopause, menopause, or post menopause. Approximately 75 million women in the United States are currently navigating this period of life with roughly 1.3 million American women transition into menopause each year.
The U.S. menopause treatment market size was valued at USD 5.36 billion in 2024 and is expected to reach USD 7.72 billion by 2032, growing at a CAGR of 4.63% over 2025-2032.
The global women's health devices market, is expected to grow significantly, potentially reaching $107.81 billion by 2031.
https://menopausefoundationcanada.ca/menopause-in-canada-report
https://www.snsinsider.com/reports/menopause-treatment-market
https://www.grandviewresearch.com › industry-analysis